Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. November 2024 09:00 ET | Quelle: Vilya, Inc.

Vilya Announces Exclusive License Agreement of RFdiffusion-based Generative Model from the University of Washington for the Design of Macrocyclic Peptides

– License of proprietary RFdiffusion-based model, RFpeptides, provides Vilya with another powerful structure prediction framework for rapid and unique design of potent and selective macrocycles for...
04. Juni 2024 09:00 ET | Quelle: Vilya, Inc.

Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines

Founder and lead investor ARCH Venture Partners is joined by NVIDIA’s NVentures, Menlo Ventures, and MadronaFunding accelerates advancement of Vilya's proprietary computational drug design and...
25. April 2024 14:00 ET | Quelle: Vilya, Inc.

Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles

– Company creating de novo designed macrocycles with enhanced efficacy that precisely target disease biology – Vilya’s privileged macrocycles have the potential to be applied across broad...